The preclinical rationale for petosemtamab is supported by evidence that LGR5 is upregulated in a wide range of solid tumors, including up to 89% of HNSCC cases, and is often induced following EGFR inhibition [98]. Here, EGFR is linked to head and neck squamous cell carcinoma.